Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
about
Invasive Bladder Cancer: Genomic Insights and Therapeutic PromiseMitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical UtilityCDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Emerging strategies to overcome resistance to endocrine therapy for breast cancer.SCF ubiquitin ligase-targeted therapies.The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.RB Loss Promotes Prostate Cancer Metastasis.Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerCDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Effect of food on the bioavailability of palbociclib.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Profiling of the metabolic transcriptome via single molecule molecular inversion probes.Genomic landscape of salivary gland tumors.Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.Optimization and validation of RP-HPLC method for simultaneous estimation of palbociclib and letrozole.Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.Updates on managing advanced breast cancer with palbociclib combination therapyUpdate on adjuvant chemotherapy for early breast cancerIntegrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
P2860
Q28088334-3CCCA581-E7A0-4B98-B088-2F44A941E30EQ28548371-30B85CAF-6B23-4E95-BA71-51D02CBBE0F0Q34227791-710708EF-578E-41BB-BE01-9368A07C7387Q34706060-63F9D0D2-6EC5-4148-B061-84BBCCCDC58CQ35180940-109CFED6-CD1F-4D36-BDC7-E83FD2237CFDQ36188947-6C2BAF1C-2FAD-4918-8F58-E9CF8D496768Q36303134-5BB2655C-C55F-4BD3-A66A-5BF367E0D15DQ36562082-0B116001-A566-4342-BB07-60125AE3D54EQ37272774-BD801B18-6CEB-46E8-B839-219DA303559FQ37570653-509089D0-9E83-4771-A616-10D772730C89Q38221463-A0B93D94-D38E-454C-9709-DB422706CC46Q38267996-3D0F16C8-9208-4750-A4E6-4367775F9599Q38286180-57F2E47F-1946-4E4D-A7DC-DD573A9AAB00Q38349784-379013E2-82CE-4444-9CB6-49263962B03DQ38605171-50C4FA1C-2254-4908-9946-8AD353C9818CQ38727367-B52BB5E2-248A-4833-BF1F-A92A07EDF2AEQ38743546-504264F1-BFE1-423A-BBD7-810BE9DCDA04Q38751569-B54A1F43-102D-457B-9E6E-A222F5DB65C7Q38870640-04BD95F4-1F31-4BED-9346-22627613379FQ38958668-320B851D-3FCC-4C3F-BAB3-8A0C6AE3AD69Q41133627-717A9CDD-6D8E-4F71-BF8D-F322D0150BB5Q41198110-5340336F-01C3-4124-8651-EA7F188145DDQ41546576-5A136DC0-F69D-4DAB-A8BB-750557FDAAE4Q42070222-241CBE19-BCF7-4188-9E20-3F0453CD77A8Q42775668-066D95B7-D6B5-4190-BE0C-C5032CA06785Q43281043-54202F52-D6E0-4BC9-B262-A77611DC5055Q48239334-8A2AE632-B963-4995-BA88-128BBCE3D4F8Q49787815-A2E74D32-9DC2-40C3-8CC2-655F192DC473Q57106487-E9A7A056-2346-4877-B805-CCC45A3E815AQ57126532-DAF349BE-268E-4783-B01B-E7709D783FF3Q58711257-DCF1B108-A576-46D4-9510-3789F8E0AD13
P2860
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@ast
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@en
Palbociclib
@nl
type
label
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@ast
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@en
Palbociclib
@nl
prefLabel
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@ast
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@en
Palbociclib
@nl
P2093
P2860
P1476
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
@en
P2093
Alessio Schirone
Andrea Rocca
Dino Amadori
P2860
P304
P356
10.1517/14656566.2014.870555
P407
P577
2013-12-26T00:00:00Z